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Abstract It has previously been shown that expression of the 
inducible form of NO synthase (EC 1.14.23) is controlled at the 
transcriptional level and that induction of iNOS transcription is 
dependent on activation of transcription factors of the NFr~B 
family. TNF-~ and IL-I[~ synergistically stimulate iNOS 
transcription in rat glomerular mesangial cells. We have recently 
reported that endothelin-1 completely blocks cytokine-induced 
iNOS expression at the transcriptional level. To further 
investigate the molecular mechanisms and the role of NFgB in 
cytokine-elicited iNOS transcription, we cloned a 661 bp 
genomic rat DNA fragment, which contains 497 bp of the 
proximal iNOS promoter. An NFgB-binding site identical to 
that described for the murine sequence was identified and used 
for electrophoretic mobility shift experiments. We found that 
binding of NFgB is strongly induced in mesangial cells by both 
IL-I[~ and TNF-~. While endothelin-1 blocks cytokine-induced 
iNOS expression, it has no influence on the binding pattern of 
NFgB. We conclude from these data that transcription of iNOS 
in mesangial cells requires additional signals besides activation of 
NFw, B. 
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hibitory effects have been shown for TGF-I3, PDGF, IL-4, 
glucocorticoids, cyclosporin A, angiotensin II and endothe- 
lin-I (ET-I). These studies were performed mainly in macro- 
phages [8-10] as well as vascular smooth muscle cells 
(VSMCs) or MCs [11-17]. Most of the inhibitory effects occur 
at the transcriptional level. On the other hand, posttranscrip- 
tional and posttranslational effects, e.g. for TGF-I3 , have also 
been described. The published ata show that the regulation 
of iNOS expression is highly cell and species specific. This 
renders the elucidation of a universal signaling pathway for 
iNOS regulation more difficult. Cloning of murine [18], hu- 
man [19,20] and rat iNOS promoters has enabled us to exam- 
ine transcriptional effects with authentic promoter fragments. 
We have recently reported that ET-1 inhibits iNOS expres- 
sion induced by TNF-c~ and IL-I[3 via the ETA receptor in rat 
MCs [17]. Our data indicated that the inhibition occurs at the 
transcriptional level. The present study was performed to 
further improve our understanding of the molecular mechan- 
isms involved in the inducing or inhibitory effects on iNOS 
expression. 
2. Materials and methods 
1. Introduction 
Considerable amounts of nitric oxide (NO) are produced by 
the inducible form of NO synthase in experimental glomerular 
disease [1]. NO is thought o function as an important medi- 
ator of the inflammatory response, e.g. by exerting toxic ef- 
fects on glomerular ceils or by affecting the apoptotic or pro- 
liferative cell phenotype. In fact, blocking of NO production 
by the NOS inhibitor, L-NMMA, has been shown to attenu- 
ate the severity of glomerular injury induced by anti-thymo- 
cyte serum [2]. Infiltrating activated macrophages release in- 
terleukin-ll3 (IL-I[~) and tumor necrosis factor (TNF-~), 
which induce the macrophage-type NO synthase (iNOS or 
NOS II) in mesangial cells (MCs) [3,4]. The induction of 
iNOS is regulated not only by these inflammatory cytokines 
and endotoxin but also by other factors, such as cAMP-ele- 
vating agents [5,6] and basic fibroblast growth factor [7]. In- 
*Corresponding author. Fax: (49) (9131) 859209. 
Abbreviations." ET-1, endothelin-1; GAPDH, glyceraldehyde-3-phos- 
phate dehydrogenase; IL-I[3, interleukin 113; iNOS, inducible nitric 
oxide synthase; MCs, mesangial cells; NF~cB, nuclear factor kappa B; 
PDTC, pyrrolidone dithiocarbamate; PMA, phorbol 12-myristate 13- 
acetate; TNF-~, tumor necrosis factor-c~ 
The nucleotide sequence data reported in this article have been 
deposited in the GenBank data library (accession no. Z69839). 
2.1. Reagents 
Human recombinant IL-I[3 and ET-1 were purchased from Boeh- 
ringer (Mannheim, Germany). Human recombinant TNF-a was a gift 
from BASF/Knoll (Ludwigshafen, Germany). DNA sequencing was 
performed with kits from Pharmacia (Freiburg, Germany) or Boeh- 
ringer Mannheim. The cloning vector pBluescript KS + and all mate- 
rials used for electrophoretic mobility shift assay (EMSA) as well as 
control oligonucleotides for NF~cB and oct-1 were obtained from 
Stratagene (Heidelberg, Germany). Radioactive products and nylon 
blotting membranes were obtained from Amersham Buchler 
(Braunschweig, Germany). Tissue culture plastic was from Falcon 
(Becton-Dickenson, Heidelberg, Germany), media, sera and Taq po- 
lymerase from Gibco-BRL (Eggenstein, Germany). All other chemi- 
cals were purchased from Sigma (Deisenhofen, Germany). 
2.2. Cell culture 
For preparation and culture of glomerular MCs from male Sprague 
Dawley rats, standard techniques were used, as described previously 
[21]. MCs were cultured in Dulbecco's minimal essential medium 
supplemented with 10% heat-inactivated fetal calf serum (FCS), 
2 mM glutamate, 5 ng/ml insulin, 100 U/ml penicillin and 1 mg/ml 
streptomycin (all from Sigma). To obtain quiescent cells, MCs were 
maintained in medium containing 0.5% FCS for 4 days before cyto- 
kine treatment. MCs were used between passages 8 and 19. In most 
experiments, he cytokines IL-I[~ and TNF-~ were used at concentra- 
tions of 25 U/ml and 25 ng/ml, respectively. 
2.3. Northern blot analysis 
Using a murine cDNA clone kindly provided by Dr. Xie [18], iNOS 
RNA was detected by Northern blot hybridization as described pre- 
viously [17]. For equivalent loading of the RNA probes, correction 
was carried out after rehybridization of the filter with a GAPDH 
probe. 
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2.4. Cloning and sequencing of the rat iNOS promoter 
Genomic DNA from whole rat liver was prepared as described 
previously [22]. A genomic DNA fragment of 661 bp length was 
amplified by the polymerase chain reaction (PCR) technique using 
the primers 5' CGGATCCTAGGCTAACAAGACCCAAG 3' and 
5' ATCCTTTCTAGAAAACCTCC 3' referred to as N5 and N6, 
respectively. The PCR product was extracted from an agarose gel 
[23] and cloned into the respective sites of the pBluescript KS + clon- 
ing vector (Stratagene). Sequencing of the cloned DNA (designated 
pINOSGEN2) was performed using a recently reported variant of 
Sanger's dideoxynucleotide chain termination method [24,25]. 
2.5. Electrophoretic mobifity shift assay ( EMSA ) 
1 × 107 MCs, were treated with combinations of cytokines/ET-I or 
vehicle (see Section 3). Nuclear proteins were extracted as described 
by Schreiber et al. [26]. Routinely, 6 [.tg of the extract were used for 
each experiment. With pINOSGEN2 as template DNA and the pri- 
mers 5' AATGCATACAGACTAGG 3' (N9) and 5' GGTATrTA- 
TACCCATCC 3' (N10), PCR was performed, to amplify a 127 bp 
DNA fragment containing a NF~cB site (subsequently referred to as 
PCR127). Due to the lack of 5'-phosphate groups, this PCR product 
could be directly labeled with 32p after purification by gel electrophor- 
esis. For some experiments, a double-stranded oligonucleotide, repre- 
senting a NF~B element with the sequence 5' GATCGAGGG- 
GACTTTCCCTAGC 3', was labeled and used for the binding 
assay. The subsequent s eps were performed following the recommen- 
dations of the distributor (Stratagene). To verify binding of the pre- 
dicted nuclear protein, competition assays were performed with 5- 
100-fold molar excess of the unlabeled NF~B probe, unlabeled 
PCR127 or a double-stranded oligonucleotide which represents an 
oct-I binding site (5' GATCGAATGCAAAT CACTAGCT 3'). 
3. Results 
The transcription factor NF~cB is thought to be one of the 
most important nuclear proteins involved in mediating cyto- 
kine-induced transcription of the macrophage-type iNOS. 
This was first shown in murine macrophages in gel shift and 
transient ransfection studies [27]. As in macrophages, in MCs 
and other kidney cells, the induction of iNOS is inhibited by 
the NF~cB inhibitor PDTC [28 30]. We have recently shown 
that ET-I exerts a powerful inhibitory effect on cytokine-in- 
duced iNOS transcription in MCs [17]. To further elucidate 
this observation, we cloned a 637 bp genomic iNOS DNA 
fragment, which represents 497 bp of the rat iNOS promoter 
as well as 139 bp of exon 1. This was achieved by PCR, using 
primers which are homologous to known iNOS sequences 
from mouse (genomic) and rat (eDNA). Oligonucleotide N5 
was a homologue to the 5'-region of the iNOS cDNA found 
in rat VSMCs [31] as well as in rat hepatocytes [32] and was 
extended with a BamH1 site. N6 was designed to match ex- 
actly the mouse promoter on position -427 to -408 [18]. N6 
contains an intrinsic Xbal site of the murine iNOS promoter. 
The cloned rat DNA fragment was about 100 bp longer than 
expected in comparison to the murine promoter. Sequence 
analysis showed high homology to the previously cloned mu- 
rine iNOS promoter ( > 90%) apart from a gap of 93 bp in the 
upstream region (Fig. 1). In particular, all putative or pres- 
ently established binding sites for transcription factors derived 
from the murine iNOS promoter were also found in the rat 
promoter. 
Firstly, we examined the effects of IL-I[3 and TNF-ct on the 
activation of NFKB using a synthetic, double-stranded oligo- 
nucleotide which represents a common NFIcB consensus e- 
quence. Nuclear extracts of MCs, which had been treated with 
IL-I[3 and TNF-ct for 5 h showed enhanced binding of NF~cB 
to the DNA probe compared to nuclear extracts obtained 
-510 TC TAG~AAC CT~C C GATGAATGGTTCC TGGGCGTGTI 'GGAATATTGGCA 
llJiilllllllll lllllllr llIIlllllfllllfilllllllll 
-421 TC TAGAAAAC C TC CTC-ATGAATGTGTCCTGGGC GTG~AATATTGGCA 
~460 C C ATCTAACC, C ACTGGTCATTTGGAACCTGGAC'i-z%T J."F'f C CGGCATGAT 
lililIll 
-371 CCATCTAA . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
-410 C C ACACTGC C AGTAATCCACAGATTTCTGGAC TTC TC-C TACAAACTGCAA 
li ill 
-363 CCTCAC . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  
-360 ATGAGAGAACAGACAGAAATGAACCAGAGTGCTC ATG C C CAGAAC AAAA 
[ilillIIlilllilll I lI[IIl IIIII IIIIIIIIIIIIII 
- 357 . TGAGAGAACAGACAGAA. . .  AC-CCAGAGAGCTCCGTGCCCAGAACAAAA 
-310 TCCC.CAGCAGCTGCAAGCCAGGGTCTGTGGTGCAGCTAAGAAA GCCTC 
I[II llllIlI[llllliI[llll lillii lilllllllillll 
-311 TC C CTCAGCAGCTGCAAGC C AGGGTATGTGGTTTAGCTAAGAAAAGCCAG 
-261 CCT ..... C C TAGTGAGTCC AGTTTTCAAGA~ CAC TC GC TC4ZCAAGG 
Iii lllllI[llllIlilill III I i II lillll Ill 
-261 C CTC C CTCCC TAGTGAGTC C CAG'~AAGTGACTAC GTGCTC-C CTAGG 
-216 GACCA~CTTGGACTGGGGACCAGGAAGAGGTGGCCTCAC.  CGAAGAT 
I III III IIIIII II lllflllllliI IIlill I It III 
-211 GGC C ACTC-C CTTGGACGGGC GAC CAGGAAGAGA~C TTGC ATGAGGAT 
-167 ACAC C ACAGAGTGAC GTAATA~ATGCATACAGAC TA'~C, GAGTGTCCATCGC 
iflifllfl I[II lllil If I[I llllllIllllllllllill 
-161 AC ACC AC AGAGTGATGTAATCAA.  C-CACACAGACTAGGAGTGTC CATCAT 
-i17 GAATGAGCTAAC TTC-CACAC C CTAC'~GGGGACTCTCC~TTTGGGAACAGT 
ilillilllllllill11Iill llilllilllIllllllllllllIllll 
-112 GAATGAGCTAACTTGCACACCCAAC~GGGGACTCTCC~TTGGGAACAG.  
OOt-1 (WlO m~) TATA 
-67 GAC "Iw'r.~C,~I~,CA~'YrCTGCAGAGCGTGGAT~,q~CCT~. 
I[11111[11 I l l l l l [ l l l l l l  I [[ I  I l l l l l l l l l l l l l l l [ I  
- 63 .... TTATGCAAAATAC.CTCTGCAGAGCCTGGAGGGGTATAAA~IACCTGA 
~1~ ~ NIO 
-17 TGGCTACTGTCAGGGCCACAGCTTTACAGGGAGTTGAAGACTGAGACTCT 
ilill II IIIIl fill IliillllllliIlllllillllilllil 
-17 TGGCTC-CTGC AGGGTCACAAC TTTACAGGGAGTTGAAGAC TGAGACTCT 
~'34 GGC C CCACGGGACACAGTGTC GCTGGTTTGAAACTTCTTAGC CAC CTTGG 
lllilllll Irlllllllll llilllllIlli[lll fliIIIlliII 
+34 GGC CC CAC GGGACACAGTGTCAC TGGTTTGAAACTTCTC AGCCACC'~ 
+84 TGAGGGGAC TGGAC TTTTAGAGAC G~ CTGAGGTTCCTCAGGC TTGGGT 
III lllilll II liilllll Ililllfll llllil [llllf[l 
+64 TG.~G~ACTGA~2T~"TAGAGAC AC'P'~CTGAG~ TCCT CACG~_.T 
+134 CTTGTT 
+134 CTTGTT 1727 
Fig. 1. Nucleotide sequence of the genomic lone, pINOSGEN2 in 
comparison to the respective murine sequence. The TATA box as 
well as the binding sites for oct-1 and NFrB, which were examined 
in this study, are boxed (for further details see [18]). The arrows in- 
dicate the primers N5 and N6 used to amplify the rat iNOS promo- 
ter from liver DNA. The sequence represented by N6 belongs to the 
murine iNOS promoter and does not necessarily exactly match the 
rat promoter (broken line). The arrows N9 and N10 represent the 
position of the primers, used to amplify a 127 bp fragment, which 
was used for EMSA. 
from untreated MCs (Fig. 2). These results show that TNF-  
t~ and IL-11] induce translocation of active NF~B to the nu- 
cleus. Addition of a 5-fold molar excess of the unlabeled PCR 
product PCR127 (see Fig. 1) to the binding assay resulted in a 
clear competition, suggesting that the NF~B element in the 
proximal iNOS promoter, which has recently been described 
as essential for iNOS transcription [27], is able to bind its 
transcription factor. 
To detect further nuclear proteins which bind to the prox- 
imal iNOS promoter egion in MCs treated with cytokines or 
vehicle, we used the radiolabeled PCR fragment PCR127, 
which contains an oct-1 binding site besides the NF~cB ele- 
ment mentioned above, as predicted by computer analysis 
(Fig. 1). As shown in Fig. 3, EMSA studies with nuclear 
proteins from MCs treated with TNF-t~+IL-I[3 or vehicle re- 
vealed at least two different protein/DNA complexes. One of 
them, which is strongly induced by IL-1]3 and TNF-tA was 
characterized as the NFKB/DNA complex (Fig. 3b) as shown 
by competition experiments. The complex with lower retarda- 
tion was identified as an oct - l /DNA complex by competition 
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Fig. 2. Activation of NF~cB in MCs treated with cytokines or vehi- 
cle. MCs were treated with TNF-0~+IL-1[3 (T+I) or vehicle (control) 
for 5 h. Nuclear extracts were prepared and incubated with a radio- 
labeled oligonucleotide containing a NF~B consensus sequence. Par- 
tial competition was reached by adding a 5-fold molar excess of the 
unlabeled fragment PCR127 [+], which contains the proximal NF~cB 
site of the rat iNOS promoter (see Section 2). The protein/DNA 
complexes were analyzed on a 8% PAA gel in 0.25 × TBE buffer. 
with an oct-1 representing double-stranded oligonucleotide 
(Fig. 3a). 
As shown in Fig. 4, IL-113 and TNF-c~ have a strong syner- 
gistic effect on iNOS transcription i MCs, which is inhibited 
by ET-1. Inhibition of cytokine-mediated iNOS mRNA in- 
duction by ET-1 is due to transcriptional inhibition of iNOS 
expression since ET-I does not reduce iNOS mRNA stability. 
The half-life of iNOS mRNA in the absence of ET-1 was 1.1 h 
(mean of two independent experiments giving similar data) 
and in the presence of ET-1, the half-life was 1.7 h (data 
not shown). This indicates that ET-1 does not accelerate 
iNOS mRNA degradation. IL-113 or TNF-ct, when given 
alone, yield only weak or no detectable iNOS mRNA signals 
(Fig. 4a, upper panel). Binding of NF~B to the 127 bp radio- 
labeled DNA fragment PCR127 was induced after stimula- 
tion with TNF-a plus IL-I~, as found by EMSA. Addition 
of either TNF-a or IL-1 [~ induced strong binding of NF~B to 
the iNOS promoter (Fig. 4a, lower panel). This finding sug- 
gests that translocation of NFKB to the nucleus is not suffi- 
cient for the transcription of iNOS. This is corroborated by 
the observation that ET-1 cannot change the binding pattern 
of NF~cB elicited by TNF-e~ and by IL-I~ (Fig. 4b), although 
ET-1 completely blocks cytokine-induced increases in iNOS 
mRNA steady-state levels. 
4. Discussion 
Among others, dexamethasone, aspirin and cyclosporin 
have been shown to inhibit NF~B binding to the promoters 
of some cytokine-inducible g nes, including iNOS [33--40]. 
Different mechanisms have been considered to inhibit NF~B 
activation. The role of glucocorticoids has been studied most 
intensely. Their inhibitory effects on NF~:B activation have 
been described to involve transcriptional ctivation of the 
physiological NF~B inhibitor, IKB [35,36], e.g. via direct in- 
activation of the p65 subunit of NFKB by the activated glu- 
cocorticoid receptor [37,38] or through changes in the redox 
state in the cell [39,40]. Since ET-1 does not lead to any 
changes in the binding pattern of NF~zB, the data suggest 
that none of these effects plays a significant role in the inhib- 
itory action of ET-1 on iNOS expression i  MCs during time 
periods between 2 and 14 h. These periods were used for 
Northern blot analysis and EMSA, where ET-1 exerted a 
strong inhibitory effect on cytokine-induced iNOS mRNA 
expression but showed no detectable changes in the binding 
pattern of NFKB. Another consideration is that ET-1 could 
induce binding of a nuclear protein which occupies the NF~cB 
site and consequently prevents binding of NF~cB. Therefore, 
we decided to clone the proximal part of the iNOS promoter 
which contains a NF~B site. This enabled us to examine the 
binding of NF~B not only with a synthetic and established 
double-stranded consensus oligonucleotide, but also with an 
authentic fragment of the rat iNOS promoter where the 
NF~cB site is embedded in the correct context. 
As mentioned above, there are species-specific variations in 
the regulation of iNOS in MCs. Human iNOS is only ex- 
a) b) 
oct-1 oct-1 NFKB NFKB 
+ - + + + 
NFKB - -  
oct-R - -  
I I I  I I i t  J 
control T+I control T+I  
Fig. 3. Identification of an oct-I and a NF~B element by competition analysis. MCs were treated with TNF-c~ (T) plus IL-11~ (1) or vehicle for 
5 h. Nuclear proteins were incubated with radiolabeled probe PCR127. Competition was performed with a 100-fold molar excess of an oct-1 
(a) or a NFKB element (b) containing oligonucleotide [+]. 
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INOS mRNA 
a- - - . -a  I I , , i~  K~- I  L . . . -n  n . . .~m ¢ . . __a  ¢ . .~ i  
control I T T+I control T+I T+I+E 
" 4 -  + " + + - - - 
NF~B 
Fig. 4. Effects of TNF-c~ (T), IL-II3 (I) and TNF-c~+IL-I[3 (T+I) (a) or of TNF-a+IL-113+ET-1 (T+I+E) (b) on iNOS transcription and binding 
of NF~B. MCs were treated with the indicated agents for 15 h (Northern blot) or 5 h (EMSA). Total mRNA was subjected to Northern blot- 
ting (upper panel) with an iNOS probe. Nuclear protein extracts were incubated with the radiolabeled fragment PCR127 and the complexes 
run on a 6% PAA gel (lower panel). Binding of NF~cB was verified by competition with a 100-fold molar excess of the NF~B specific oligonu- 
cleotide. 
pressed when combinations of endotoxin, interferon-y, TNF-ct 
and IL-1]3 are given as cocktails [41]. In contrast o rat MCs, 
iNOS is coinduced in murine MCs by the PKC activator 
PMA [42], which inhibits cytokine-induced iNOS expression 
in rat MCs (Fees, H. and Beck, K.-F., unpublished observa- 
tions). Therefore, we considered the rat promoter as a useful 
tool to detect differences in the iNOS promoters, cloned so far 
[18-20 I.
Besides a NF~B site, the 127 bp proximal promoter frag- 
ment used in this study contains a putative TNF-RE and an 
interferon- responsive lement (IRE), as described by Xie et 
al. [18]. Additionally, we could identify sequence homology to 
an oct-1 site. A nuclear protein binding to the respective pro- 
moter region is presumably constitutively expressed in rat 
MCs. Binding of active NF~:B (presumably representing 
p50/50 and p50/p65 dimers) and the oct-l-protein could be 
demonstrated by competition experiments. The role of the 
TNF-RE remains unclear, but preliminary results using a 
DNA fragment representing this region suggest hat binding 
to this element may be enhanced by ET-1 while it is not 
influenced by TNF-a.  This divergence could explain the in- 
hibitory effect of ET-1 on iNOS induction. This concept re- 
mains to be validated by further experiments. In summary, we 
conclude from our observations that cytokine-induced tran- 
scription of iNOS in rat MCs requires additional signals be- 
sides activation of NF~cB. 
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